Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01K-063/00
A61K-031/495
A61K-031/405
A61K-031/20
A61K-035/28
C12N-005/0775
A61K-035/32
출원번호
US-0216430
(2014-03-17)
등록번호
US-9808454
(2017-11-07)
발명자
/ 주소
Bar-Or, David
Thomas, Greg
출원인 / 주소
Ampio Pharmaceuticals, Inc.
대리인 / 주소
Sheridan Ross P.C.
인용정보
피인용 횟수 :
1인용 특허 :
113
초록
The invention provides compositions that increase the mobilization, homing, expansion, and/or differentiation of stem cells and methods of using the same for the treatment of mammals.
대표청구항▼
1. A method of expanding bone marrow derived mesenchymal stem cells, comprising (a) contacting the mesenchymal stem cells with DA-DKP, wherein the DA-DKP is in a composition comprising a less than 5000 molecular weight fraction of human serum albumin, and(b) culturing the stem cells under conditions
1. A method of expanding bone marrow derived mesenchymal stem cells, comprising (a) contacting the mesenchymal stem cells with DA-DKP, wherein the DA-DKP is in a composition comprising a less than 5000 molecular weight fraction of human serum albumin, and(b) culturing the stem cells under conditions suitable to facilitate the expansion of the mesenchymal stem cells. 2. A method of providing mammalian bone marrow derived mesenchymal stem cells to a mammal, comprising: (a) contacting the mesenchymal stem cells with DA-DKP, wherein the DA-DKP is in a composition comprising a less than 5000 molecular weight fraction of human serum albumin,(b) cultivating the mesenchymal stem cells under conditions suitable to facilitate the expansion of the cells; and(c) introducing the expanded cells into a mammal. 3. A method of causing bone marrow derived mesenchymal stem cells to differentiate into a particular type of cell comprising: (a) contacting the mesenchymal stem cells with DA-DKP, wherein the DA-DKP is in a composition comprising a less than 5000 molecular weight fraction of human serum albumin;(b) cultivating the mesenchymal stem cells under conditions suitable to facilitate the expansion of the stem cells; and(c) adding one or more differentiation factors or changing culturing conditions to induce differentiation of the mesenchymal stem cells to form a different type of cell. 4. A method of providing differentiated cells, to a mammalian subject, comprising: (a) contacting mammalian multipotent bone marrow derived mesenchymal stem cells with DA-DKP, wherein the DA-DKP is in a composition comprising a less than 5000 molecular weight fraction of human serum albumin;(b) cultivating the mesenchymal stem cells under conditions suitable to facilitate the expansion of the mesenchymal stem cells;(c) adding one or more differentiation factors or changing culturing conditions to induce differentiation of cells to form a different type of cell; and(d) introducing the differentiated cells into the subject. 5. The method of claim 1, wherein the DA-DKP composition further comprises N-acetyl tryptophan, caprylate and/or caprylic acid. 6. The method of claim 1, wherein the DA-DKP composition comprises a fraction of human serum albumin, wherein substantially all of the albumin has been removed from the fraction. 7. The method of claim 1, wherein the low molecular weight fraction of human serum albumin is produced by filtration. 8. The method of claim 1, wherein the step of contacting the mesenchymal stem cells with DA-DKP has an effect selected from the group consisting of increasing production of a protein selected from the group consisting of CXCR4, MMP14, MMP13, aggrecan, SDF1, collagen 2A1 and combinations thereof and decreasing production of CXCL12. 9. The method of claim 1, wherein the step of culturing includes the addition of one or more components selected from the group consisting of thrombopoietin (TPO), stem cell factor (SCF), IL-1, IL-3, IL-7, flt-3 ligand (flt-3L), G-CSF, GM-CSF, Epo, FGF-1, FGF-2, FGF-4, FGF-20, IGF, EGF, NGF, LIF, PDGF, bone morphogenic proteins (BMP), activin-A, VEGF, forskolin, and glucocorticords. 10. The method of claim 2, wherein the DA-DKP composition further comprises N-acetyl tryptophan, caprylate and/or caprylic acid. 11. The method of claim 2, wherein the DA-DKP composition comprises a fraction of human serum albumin, wherein substantially all of the albumin has been removed from the fraction. 12. The method of claim 2, wherein the low molecular weight fraction of human serum albumin is produced by filtration. 13. The method of claim 2, wherein the step of contacting the mesenchymal stem cells with DA-DKP has an effect selected from the group consisting of increasing production of a protein selected from the group consisting of CXCR4, MMP14, MMP13, aggrecan, SDF1, collagen 2A1 and combinations thereof and decreasing production of CXCL12. 14. The method of claim 2, wherein the step of cultivating includes the addition of one or more components selected from the group consisting of thrombopoietin (TPO), stem cell factor (SCF), IL-1, IL-3, IL-7, flt-3 ligand (flt-3L), G-CSF, GM-CSF, Epo, FGF-1, FGF-2, FGF-4, FGF-20, IGF, EGF, NGF, LIF, PDGF, bone morphogenic proteins (BMP), activin-A, VEGF, forskolin, and glucocorticords. 15. The method of claim 3, wherein the DA-DKP composition further comprises N-acetyl tryptophan, caprylate and/or caprylic acid. 16. The method of claim 3, wherein the DA-DKP composition comprises a fraction of human serum albumin, wherein substantially all of the albumin has been removed from the fraction. 17. The method of claim 3, wherein the low molecular weight fraction of human serum albumin is produced by filtration. 18. The method of claim 3, wherein the step of contacting the mesenchymal stem cells with DA-DKP has an effect selected from the group consisting of increasing production of a protein selected from the group consisting of CXCR4, MMP14, MMP13, aggrecan, SDF1, collagen 2A1 and combinations thereof and decreasing production of CXCL12. 19. The method of claim 3, wherein the step of cultivating includes the addition of one or more components selected from the group consisting of thrombopoietin (TPO), stem cell factor (SCF), IL-1, IL-3, IL-7, flt-3 ligand (flt-3L), G-CSF, GM-CSF, Epo, FGF-1, FGF-2, FGF-4, FGF-20, IGF, EGF, NGF, LIF, PDGF, bone morphogenic proteins (BMP), activin-A, VEGF, forskolin, and glucocorticords. 20. The method of claim 3, wherein the step of adding one or more differentiation factors or changing culturing conditions comprises a step selected from the group consisting of alteration in temperature, alteration in oxygen/carbon dioxide content, alteration in media turbidity, and addition of a differentiation factor selected from nutrients, enzyme inhibitors, enzyme stimulators, histone deacetylase activity inhibitors, DNA methyltransferase activity inhibitors, and enzyme GSK-3 inhibitors. 21. The method of claim 4, wherein the DA-DKP composition further comprises N-acetyl tryptophan, caprylate and/or caprylic acid. 22. The method of claim 4, wherein the DA-DKP composition comprises a fraction of human serum albumin, wherein substantially all of the albumin has been removed from the fraction. 23. The method of claim 4, wherein the low molecular weight fraction of human serum albumin is produced by filtration. 24. The method of claim 4, wherein the step of contacting the mesenchymal stem cells with DA-DKP has an effect selected from the group consisting of increasing production of a protein selected from the group consisting of CXCR4, MMP14, MMP13, aggrecan, SDF1, collagen 2A1 and combinations thereof and decreasing production of CXCL12. 25. The method of claim 4, wherein the step of cultivating includes the addition of one or more components selected from the group consisting of thrombopoietin (TPO), stem cell factor (SCF), IL-1, IL-3, IL-7, flt-3 ligand (flt-3L), G-CSF, GM-CSF, Epo, FGF-1, FGF-2, FGF-4, FGF-20, IGF, EGF, NGF, LIF, PDGF, bone morphogenic proteins (BMP), activin-A, VEGF, forskolin, and glucocorticords. 26. The method of claim 4, wherein the step of adding one or more differentiation factors or changing culturing conditions comprises a step selected from the group consisting of alteration in temperature, alteration in oxygen/carbon dioxide content, alteration in media turbidity, and addition of a differentiation factor selected from nutrients, enzyme inhibitors, enzyme stimulators, histone deacetylase activity inhibitors, DNA methyltransferase activity inhibitors, and enzyme GSK-3 inhibitors.
Chuntharapai Anan (Colma CA) Lee James (So. San Francisco CA) Hebert Caroline (San Francisco CA) Kim K. Jin (Los Altos CA), Antibodies to human IL-8 type A receptor.
Campbell David ; Look Gary C. ; Szardenings Anna Katrin ; Patel Dinesh V., Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use.
Biftu Tesfaye ; Cai Xiong ; Hussoin Sajjat ; Grewal Gurmit ; Shen T. Y., Compounds and methods for the treatment of cardiovascular inflammatory and immune disorders.
Biftu Tesfaye (Belmont MA) Cai Xiong (Framingham MA) Hussion Sajjet (Lexington MA) Grewal Gurmit (Waltham MA) Shen T. Y. (Charlottesville VA), Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders.
Biftu Tesfaye ; Scannell Ralph ; Cai Xiong ; Hussoin Sajjat, Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders.
Biftu Tesfaye ; Scannell Ralph ; Cai Xiong ; Hussoin Sajjat, Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders.
Cai Xiong (Framingham MA) Fura Aberra (Cambridge MA) Qian Changgeng (Wayland MA), Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders.
Cai Xiong ; Hussoin Sajjat ; Hwang San-Bao ; Killian David ; Shen T. Y., Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygen.
Cai Xiong (Allston MA) Hussoin Saijat (Cambridge MA) Hwang San-Bao (Wayland MA) Killian David (Cambridge MA) Shen T. Y. (Charlottesville VA), Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenas.
Cai Xiong (Allston MA) Hussoin Sajjat (Cambridge MA) Hwang San-Bao (Wayland MA) Killian David (Cambridge MA) Shen T. Y. (Charlottesville VA), Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenas.
Cai Xiong (Allston MA) Hussoin Sajjat (Lexington MA) Hwang San-Bao (Wayland MA) Killian David (Cambridge MA) Shen T. Y. (Charlottesville VA), Compounds and methods for the treatment of inflammatory and immune disorders.
Pickenhagen Wilhelm (Onex CH) Dietrich Paul (Chene-Bourg CH) Keil Borivoj (St. Remy les Chevreuse FR) Lederer Edgar (Sceaux-Seine FR), Flavoring with mixtures of theobromine and cyclic dipeptides.
Berezenko Stephen,GBX ; Woodrow John R.,GBX ; Johnson Richard A.,GBX ; Wood Patricia C.,GBX ; Burton Steven J.,GBX ; Quirk Alan V.,GBX ; Coghlan David St. J.,GBX ; Wilson Mark J.,GBX, High purity albumin.
Benson Bradley J. (Chapel Hill NC) Chen Xiannong (Athens GA) Cianciolo George J. (Chapel Hill NC) Diaz Jose-Luis (Durham NC) Ishaq Khalid S. (Chapel Hill NC) Morris-Natschke Susan L. (Apex NC) Uhing , Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines.
Campbell David ; Look Gary C. ; Szardenings Anna Katrin ; Patel Dinesh V., Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use.
Steiner Solomon S. (Mount Kisco NY) Rhodes Christopher A. (Stamford CT) Shen Gregory S. (Hartsdale NY) McCabe R. Tyler (Yorktown NY), Method for making self-assembling diketopiperazine drug delivery system.
Goodfellow Val S. ; McLeod Donald A. ; Gerrity James Ivan ; Laudeman Christopher P. ; Burkard Michael R., Method for preparing and identifying N-substitued 1,4-piperazines and N-substituted 1,4-piperazinediones.
Greene Mark I. ; Murali Ramachandran ; Takasaki Wataru,JPX, Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses.
Carrera Jesus E. (Madrid ESX) Esteban Almudena R. (Madrid ESX) Mann Andre (Ostwald FRX) Schoenfelder Angele (Lampertheim FRX) Schoepp Darryle D. (Indianapolis IN) Tercero Concepcion P. (Madrid ESX) W, Pharmaceutical compounds.
Collins Mark Anthony David (Berkshire GBX) Chicarelli-Robinson Maria Ines (Berkshire GBX) Bryans Justin Stephen (Berkshire GBX) Brocchini Stephen James (Highland Park NJ) Latham Christopher John (Ber, Pharmaceutical compounds.
Kenji Fukumoto JP; Shinkichi Kohno JP; Kaneo Kanoh JP; Tohru Asari JP; Hiroshi Kawashima JP; Hirokatsu Sekiya JP; Kazunori Ohmizo JP; Takeo Harada JP, Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds.
Baroudy, Bahige M.; Clader, John W.; Josien, Hubert B.; McCombie, Stuart W.; McKittrick, Brian A.; Miller, Michael W.; Neustadt, Bernard R.; Palani, Anandan; Smith, Elizabeth M.; Steensma, Ruo; Tagat, Piperazine derivatives useful as CCR5 antagonists.
Madison, Edwin L.; Brunck, Terence K.; Semple, Joseph Edward; Lim-Wilby, Marguerita; Pryor, Kent E.; Lewis, II, Ronald D.; Duncan, David F.; Lawrence, C. Maxwell, Plasminogen activator inhibitor antagonists.
Loder Cari,GBX, Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and possibly a vitamin B12 compound.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.